Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018

October 19, 2018 – The CHMP recommended six medicines for approval, three extensions of indications and elected its new vice-chair at its October 2018 meeting. Six medicines recommended for approval, including two orphan medicines. The CHMP recommended granting a marketing authorisation for Takhzyro (lanadelumab), the first monoclonal antibody therapy for the prevention of recurrent attacks of hereditary angioedema (HAE). This medicine was reviewed … (leggi tutto)